


## AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound having the structure



wherein I is an HIV protease inhibitor selected from the group consisting of ~~ritonavir, saquinavir, amprenavir, indinavir, nelfinavir, and atazanavir~~, lopinavir, said inhibitor lacking only a hydroxyl or an amino group,

X is O or NR wherein R is H or lower alkyl,

Y is O, S or NH,

m is 0 or 1,

L is a linker comprising from 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and containing up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms may be linked in sequence, and


A is an activated functionality chosen from the group consisting of active esters, isocyanates, isothiocyanates, thiols, imidoesters, anhydrides, maleimides, thiolactones, diazonium groups and aldehydes.

2. (cancelled)
3. (original) The compound of claim 1 wherein X is O, Y is O and m is 1.
4. (original) The compound of claim 1 wherein X is NH, Y is O and m is 1.
5. (original) The compound of claim 1 wherein X is O, Y is O, m is 1 and the first atom in L adjacent to C=Y is N.
6. (original) The compound of claim 1 wherein X is NH, Y is O, m is 1 and the first atom in L adjacent to C=Y is N.

7. (original) The compound of claim 1 wherein X is NH, Y is S, m is 1 and the first atom in L adjacent to C=Y is N.
8. (original) The compound of claim 1 wherein X is NH, Y is NH and m is 1.
9. (original) The compound of claim 1 wherein X is O and m is 0.
- 10-20 (cancelled)

21. (currently amended) The compound O<sup>c</sup>-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-lopinavir-(~~6C~~).
22. (currently amended) The compound O<sup>c</sup>-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-lopinavir-(~~6D~~).
- 23-30 (cancelled)

31. (currently amended) A compound having the structure



wherein I is an HIV protease inhibitor selected from the group consisting of ~~ritonavir, saquinavir, amprenavir, indinavir, nelfinavir, and atazanavir~~, lopinavir, and atazanavir, said inhibitor lacking only a hydroxyl or an amino group,

X is O or NR wherein R is H or lower alkyl,


Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-,


-OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and



P is selected from the group consisting of polypeptides, polysaccharides and synthetic polymers, and

n is a number from 1 to 50 per 50 kilodaltons molecular weight of P.

32. (cancelled)
33. (original) The compound of claim 31 wherein P is an aminated dextran.
34. (original) The compound of claim 31 wherein P is bovine serum albumin.
35. (original) The compound of claim 31 wherein P is keyhole limpet hemocyanin.
36. (original) The compound of claim 31 wherein P is *Limulus polyphemus* hemocyanin.
37. (original) The compound of claim 31 wherein P is bovine thyroglobulin.
- 38-47 (cancelled)
48. (currently amended) The compound O<sup>c</sup>-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-lopinavir conjugate with KLH-(~~6F~~).
49. (currently amended) The compound O<sup>c</sup>-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-lopinavir conjugate with BSA-(~~6E~~).
- 50-51 (cancelled)
52. (currently amended) A compound having the structure



wherein I is an HIV protease inhibitor selected from the group consisting of ~~ritonavir, saquinavir, amprenavir, indinavir, nelfinavir,~~ lopinavir, and ~~atazanavir~~, said inhibitor lacking only a hydroxyl or an amino group,

X is O or NR wherein R is H or lower alkyl,


Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety chosen from the group consisting of -CONH-, -NHCO-, -NHCONH-, -

NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and



Q is selected from the group consisting of non-isotopic labels,

and n is a number from 1 to 50 per 50 kilodaltons molecular weight of Q.

53. (cancelled)


54. (original) The compound of claim 52 wherein Q is biotin.

55. (cancelled)

56. (currently amended) The compound O<sup>c</sup>-[4'-(1-biotinyl-amino-3,6-dioxa-octylamino)-terephthaloyl-aminocaproyl]-lopinavir ~~(6G)~~.

57-58 (cancelled)

59. (currently amended) An antibody generated in response to a compound having the structure:



wherein I is an HIV protease inhibitor selected from the group consisting of ~~ritonavir~~, ~~saquinavir~~, ~~amprenavir~~, ~~indinavir~~, ~~nelfinavir~~, lopinavir, and ~~atazanavir~~, said inhibitor lacking only a hydroxyl or an amino group,

X is O or NR wherein R is H or lower alkyl,


Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-,

-OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and



P is selected from the group consisting of polypeptides, a polysaccharides, and synthetic polymers,

and n is a number from 1 to 50 per 50 kilodaltons molecular weight of P.

60-65 (cancelled)

66. (original) An antibody generated in response to the compound of claim 48.

67-80 (cancelled)